The global acute repetitive seizures market size was USD 2.79 billion in 2023, calculated at USD 3.20 billion in 2024 and is expected to reach around USD 10.58 billion by 2034, expanding at a CAGR of 12.7% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Acute Repetitive Seizures Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Acute Repetitive Seizures Market, by Product Type, 2024-2034
8.1.1. NRL-1
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Diastat Rectal Gel
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. USL-261
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. AZ-002
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2021-2034)
9.1. North America
9.1.1. Market Revenue and Forecast, by Product (2021-2034)
9.1.2. U.S.
9.1.2.1. Market Revenue and Forecast, by Product (2021-2034)
9.1.3. Rest of North America
9.1.3.1. Market Revenue and Forecast, by Product (2021-2034)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Product (2021-2034)
9.2.2. UK
9.2.2.1. Market Revenue and Forecast, by Product (2021-2034)
9.2.3. Germany
9.2.3.1. Market Revenue and Forecast, by Product (2021-2034)
9.2.4. France
9.2.4.1. Market Revenue and Forecast, by Product (2021-2034)
9.2.5. Rest of Europe
9.2.5.1. Market Revenue and Forecast, by Product (2021-2034)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Product (2021-2034)
9.3.2. India
9.3.2.1. Market Revenue and Forecast, by Product (2021-2034)
9.3.3. China
9.3.3.1. Market Revenue and Forecast, by Product (2021-2034)
9.3.4. Japan
9.3.4.1. Market Revenue and Forecast, by Product (2021-2034)
9.3.5. Rest of APAC
9.3.5.1. Market Revenue and Forecast, by Product (2021-2034)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Product (2021-2034)
9.4.2. GCC
9.4.2.1. Market Revenue and Forecast, by Product (2021-2034)
9.4.3. North Africa
9.4.3.1. Market Revenue and Forecast, by Product (2021-2034)
9.4.4. South Africa
9.4.4.1. Market Revenue and Forecast, by Product (2021-2034)
9.4.5. Rest of MEA
9.4.5.1. Market Revenue and Forecast, by Product (2021-2034)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Product (2021-2034)
9.5.2. Brazil
9.5.2.1. Market Revenue and Forecast, by Product (2021-2034)
9.5.3. Rest of LATAM
9.5.3.1. Market Revenue and Forecast, by Product (2021-2034)
10.1. Neurelis, Inc.
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. UCB S.A.
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Valeant Pharmaceuticals North America LLC
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Alexza Pharmaceuticals
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Others
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
12.1. About Us
12.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample